Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population

Value in Health

Volumn 12, Issue 5, 2009, Pages 657-665

  Tappenden, Paul ^a   McCabe, Christopher ^b   Chilcott, Jim ^a   Simpson, Emma ^a   Nixon, Richard ^c   Madan, Jason ^a   Fisk, John D ^d   Brown, Murray ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d Capital District Health Authority   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cost utility analysis; Decision analysis model; Economic analysis; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; MITOXANTRONE; NATALIZUMAB;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MEDICARE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MEDICARE; MIDDLE AGED; MODELS, ECONOMETRIC; MULTIPLE SCLEROSIS; NOVA SCOTIA; PEPTIDES; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES; WITHHOLDING TREATMENT;

EID: 67650065019     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00485.x     Document Type: Article

References (31)

1. Compston A. McAlpine's Multiple Sclerosis. London : Churchill Livingstone, 1998.
2. The National Multiple Sclerosis Society. About MS. 2005. Available from: http://www.nmss.org/ [Accessed March 7, 2005 JH, Lucchinetti C, Rodriguez M, et al. Medical progress: multiple sclerosis. N Engl J Med 2000 343 : 938 52.
3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale. Neurology 1983 33 : 1444 52.
4. Leavitt MO. Evaluation of the Medicare Replacement Drug Demonstration: report to congress. 2007. Available from: http://www.cms.hhs.gov/ DemoProjectsEvalRpts/ [Accessed June 24, 2007 P, Chilcott JB, O'Hagan A, et al. Cost-effectiveness of beta interferon and glatiramer acetate in the management of multiple sclerosis. Report to the National Institute for Clinical Excellence. 2001.
5. Chilcott JB, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003 326 : 522 7.
6. Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis for computationally expensive models. Developments on the health economics of beta interferon and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004 8 : i 92.
7. Minden SL, Frankel D, Hadden LS, et al. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. Neurorehabilitation 2004 19 : 55 67. (Pubitemid 38241492)
8. Minden SL, Frankel D, Hadden L, et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006 12 : 24 38. (Pubitemid 43169235)
9. Ebers G. London Ontario Cohort Study. London : National Institute for Clinical Excellence, 2001 Data previously held on file).
10. Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. I Clinical course and disability. Brain 1989 112 : 133 46.
11. Patzold U, Pocklington PR. Course of multiple sclerosis: first results of a prospective study carried out on 102 MS patients from 1976-1980. Acta Neurol Scand 1982 65 : 248 66.
12. Comi G, Filippi M, Wolinsky JS, et al. European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001 49 : 290 7.
13. IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995 45 : 1277 85.
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995 45 : 1268 76.
15. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 50 : 701 8.
16. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 39 : 285 94.
17. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 43 : 655 61.
18. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998 352 : 1498 504.
19. European Study Group on Interferon beta in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 352 : 1491 7.
20. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001 57 : 1969 75.
21. Unger EF. Betaseronâ (interferon b-1b) for the treatment of secondary progressive multiple sclerosis. Medical Officer Clinical Review STN 103471. FDA. 2005.
22. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 359 : 1453 60.
23. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002 59 : 1496 506.
24. Tappenden P, McCabe C, Simpson E, et al. The clinical effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate in the management of relapsing/ remitting and secondary-progressive multiple sclerosis. Report to the Agency for Healthcare Research and Quality, 2006.
25. Brown MG. HUI3 utility data from cohort of patients in Nova Scotia. 2005. (Data on file).
26. Fisk JD, Brown MG, Sketris IS, et al. Comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005 76 : 58 63. (Pubitemid 40013492)
27. Prosser L. The Cost Effectiveness of Treatments for Multiple Sclerosis. Cambridge, MA : Harvard University, 2006.
28. O'Brien J, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003 3. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=201004 [Accessed September 23, 2005 DA, Bain P, Swan AV, et al. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 1991 48 : 299 301.
29. Ford CC. Long-term experience with current disease-modifying drugs in multiple sclerosis. J Neurol 2006 253 (Suppl. 6 S37 44.
30. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006 12 : 309 20.
31. Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Stockholm School of Economics Working Paper Series in Economics and Finance No 594. 2004;1-35.